Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
about
Multifunctional DDX3: dual roles in various cancer development and its related signaling pathwaysEribulin in Cancer TreatmentAdvances in sarcoma diagnostics and treatmentEribulin in the management of inoperable soft-tissue sarcoma: patient selection and survivalCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasMolecular Classification of Triple-Negative Breast CancerEfficacy and safety of eribulin mesylate in advanced soft tissue sarcomasGene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cellsA Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor ActivityEfficacy of eribulin in breast cancer: a short report on the emerging new data.Emerging therapies for breast cancerSynergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.Movers and shakers: cell cytoskeleton in cancer metastasis.Resistance to HER2-targeted therapies: a potential role for FOXM1.A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistanceIn vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumabSubgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast CancerEribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.Examination of Epithelial Mesenchymal Transition in Keloid Tissues and Possibility of Keloid Therapy TargetEpithelial Plasticity During Human Breast Morphogenesis and Cancer Progression.Cancer and the metastatic substrate.Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.Therapies for triple negative breast cancer.Cytoskeletal signaling in TGFβ-induced epithelial-mesenchymal transition.Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.Review on the clinical use of eribulin mesylate for the treatment of breast cancer.Eribulin in advanced liposarcoma and leiomyosarcoma.Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231.Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
P2860
Q26749143-B686B5E0-4B54-4946-99C7-79D040031AA7Q26799328-C86DC4E0-745E-49D0-8959-68AB72F53229Q28069695-1EE9B544-3638-4C32-B499-26490FFB2B81Q28074125-ADB1FA12-53EA-4D78-A62D-E52569D5B0BEQ28076210-1F8C4C51-3E7C-40BD-BB91-FC37343D3A21Q28076661-B4F3E0DE-874C-4C1E-8571-290269F24348Q28078116-3987F581-19B1-4965-B968-0A109043F89AQ28542669-72EFCAD4-C80A-42C1-8A9E-C4CF1A53817BQ28830651-53D39415-F149-4664-8B7C-18E70AF5D48EQ31167441-E9C56BFB-77DE-4221-BD83-1FC1F084E404Q33617949-26D98922-65D0-449E-921D-0C6737DD0BDBQ34062522-AD4EB2B2-376B-46D8-B6F9-914D17DAE4BAQ34466428-FE6BBA99-326F-4BAC-9BD6-4567849CF824Q34567456-C31EFC7D-4F47-459B-89B9-9C243ABDF113Q34914057-BD8D62DD-EE84-4C74-B25F-4777CD787BEFQ34955355-C1C34F4A-FB68-4241-B24C-9BC1A75584BCQ35678690-F8B7C9CA-0446-45D8-A00E-A80448EA08C1Q36389964-53CF5296-58F0-4FE2-BBD4-376DCE1C5C6CQ36614786-5CA8585B-1717-41F3-9867-8701AE2AFA4EQ36734197-C683CC24-343D-4BF0-AEE4-EA4D222CDDB8Q36742259-FC1F69FD-5F37-4EEF-8A93-BF0C69AFB577Q36922483-76E16EA2-2A17-4447-8F58-715E09B2A293Q36964337-D90EF341-B69D-43A9-B535-1F954DCD0B41Q37052387-828FD100-4F55-467F-B892-7F77CFACAC85Q37419295-1BFD65A6-736F-4341-A6B7-4C443DCC683CQ37481495-F3F1064D-67EA-48EB-97E8-039B4C4C7DB3Q37507345-74FB3008-BE85-4C0D-B81F-4AA8694C0B43Q37573461-31DCC13A-EA23-4B4B-931C-B49EBC15AAA8Q37626786-DC54C550-FF9A-4EDD-A07B-48AC9D083DA3Q37699295-E585D354-C522-47DA-B752-1F40E6EB70CEQ38267039-53BBD04B-C0DC-4564-9219-F0C398E58558Q38269966-7388322A-A007-4009-80B8-4691E1619821Q38424397-40407176-C17A-4703-9F07-456571372C15Q38626767-CF8F9F11-124B-4F21-ADF8-1760FA70497BQ38686616-594FCA90-65CB-43FE-88B9-F475E37E0547Q38688042-E4BEC900-30E1-40FD-9C9E-A0C7A53E4366Q38711371-AB891C03-AB10-4101-BACE-21F0729F5546Q38722807-AB7685A4-F6E4-4D42-B4F4-7719D62DC16CQ38819255-D9243927-3B16-4CE3-BB8F-C931E9E97513Q38924096-771B78C3-7C6F-4429-ACD7-48F3C7776276
P2860
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Eribulin mesilate suppresses e ...... helial transition (MET) states
@ast
Eribulin mesilate suppresses e ...... helial transition (MET) states
@en
Eribulin mesilate suppresses e ...... thelial-mesenchymal transition
@nl
type
label
Eribulin mesilate suppresses e ...... helial transition (MET) states
@ast
Eribulin mesilate suppresses e ...... helial transition (MET) states
@en
Eribulin mesilate suppresses e ...... thelial-mesenchymal transition
@nl
prefLabel
Eribulin mesilate suppresses e ...... helial transition (MET) states
@ast
Eribulin mesilate suppresses e ...... helial transition (MET) states
@en
Eribulin mesilate suppresses e ...... thelial-mesenchymal transition
@nl
P2093
P2860
P356
P1476
Eribulin mesilate suppresses e ...... helial transition (MET) states
@en
P2093
G Kuznetsov
S Agoulnik
Y Funahashi
P2860
P2888
P304
P356
10.1038/BJC.2014.80
P407
P577
2014-02-25T00:00:00Z
P5875
P6179
1036442359